JPRN-UMIN000031454招募中未知
Efficacy and safety of SGLT2 inhibitor in patients with diabetic kidney - Efficacy and safety of SGLT2 inhibitor in DKD
ihon University0 个研究点目标入组 40 人开始时间: 2018年2月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) age <20 years or >85 years; 2) eGFR >90 mL/min/1.73 m2 or <45 mL/min/1.73 m2; 3) HbA1c >10.0%; 4) severe heart failure, angina, myocardial infarction, or stroke occurring within 6 months before the trial; and 5) previous treatment with SGLT2 inhibitors for at least 8 weeks before the study.
研究者
相似试验
招募中
不适用
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.type 1 diabetesJPRN-UMIN000044317Hokkaido University Hospital200
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
招募中
不适用
Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease.Type 2 diabetes complicated by non-alcoholic fatty liver diseaseJPRN-UMIN000018166Toranomon Hospital, Department of Hepatology15
已完成
不适用
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30
已完成
不适用
ong-term efficacy and safety of the SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.JPRN-UMIN000037872akakinen Clinic630